Home » Stocks » GKOS

Glaukos Corporation (GKOS)

Stock Price: $47.98 USD -1.94 (-3.89%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $47.96 -0.02 (-0.04%) Jul 26, 5:09 PM
Market Cap 2.31B
Revenue (ttm) 237.59M
Net Income (ttm) -82.76M
Shares Out 45.71M
EPS (ttm) -1.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $47.98
Previous Close $49.92
Change ($) -1.94
Change (%) -3.89%
Day's Open 48.94
Day's Range 47.89 - 48.95
Day's Volume 362,830
52-Week Range 39.60 - 99.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The stock price of Glaukos, a pharmaceutical company focused on treatment of glaucoma, corneal disorders, and retinal diseases, reached its all-time high of $96 in February this year before a recent sel...

4 days ago - Forbes

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

4 days ago - Business Wire

An analyst downgraded the healthcare stock.

6 days ago - The Motley Fool

Glaukos (NYSE:GKOS) shares are trading lower after Wells Fargo downgraded the stock from Equal-Weight to Underweight.  Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company ...

6 days ago - Benzinga

Glaukos (GKOS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 week ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

1 week ago - Business Wire

Proposed rates from CMS for fiscal 2022 weren't what investors expected.

1 week ago - The Motley Fool

Centers for Medicare and Medicaid Services (CMS) issued its fiscal 2022 proposed physician fee schedule, which included two combined Category I cataract plus stent procedure codes. The physicians will u...

1 week ago - Benzinga

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

1 week ago - Business Wire

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

3 weeks ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

1 month ago - Business Wire

SEATTLE & BOSTON--(BUSINESS WIRE)--Aurion Biotech launches; Greg Kunst joins as CEO

1 month ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

1 month ago - Business Wire

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Investors continue to be optimistic about Glaukos (GKOS) owing to its strategic alliances and a strong iStent product line.

2 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

Despite reporting first-quarter loss, Glaukos' (GKOS) results reflect rise in revenues.

2 months ago - Zacks Investment Research

Glaukos (GKOS) delivered earnings and revenue surprises of 30.00% and 4.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

Glaukos (NYSE:GKOS) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's look at Glaukos's Q1 earnings report.

2 months ago - Benzinga

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

3 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

3 months ago - Business Wire

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

4 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

4 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

4 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

4 months ago - Business Wire

Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

5 months ago - Zacks Investment Research

Glaukos Corp (NYSE: GKOS) has announced topline data from the U.S. Phase 3 trial evaluating its corneal cross-linking iLink therapy to treat keratoconus. Keratoconus is characterized by cone-shaped corn...

5 months ago - Benzinga

Glaukos (GKOS) delivered earnings and revenue surprises of 93.75% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Glaukos (NYSE:GKOS) were flat after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 66.67% year over year to ($0.02), which beat the estimate...

5 months ago - Benzinga

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

5 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

5 months ago - Business Wire

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

5 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

6 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

6 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

6 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

7 months ago - Business Wire

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

8 months ago - Business Wire

Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

8 months ago - Zacks Investment Research

Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

8 months ago - Zacks Investment Research

Glaukos Corporation (GKOS) CEO Tom Burns on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Glaukos (GKOS) delivered earnings and revenue surprises of 80.43% and 19.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

8 months ago - Business Wire

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

About GKOS

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is des... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Jun 25, 2015
CEO
Thomas Burns
Employees
653
Stock Exchange
NYSE
Ticker Symbol
GKOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for GKOS stock is "Buy." The 12-month stock price forecast is 89.44, which is an increase of 86.41% from the latest price.

Price Target
$89.44
(86.41% upside)
Analyst Consensus: Buy